Skip to main content

Understanding the Benefits and Risks of Pharmaceuticals Workshop Summary (2007) / Chapter Skim
Currently Skimming:

6 Next Steps
Pages 59-60

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 59...
... • It is important to involve patients and physicians in the development of new tools for evaluating and communicating data concerning pharmaceutical benefit–risk. • It is important to improve the current system for collecting postmarketing safety and efficacy data on marketed pharmaceuticals.
Read the entire page →
From page 60...
... • Avoid assigning blame among the various stakeholders involved in benefit–risk assessment because it damages public trust. • Consider instituting citizen councils, as the United Kingdom's National Institute for Clinical Excellence did when faced with a similar crisis in public trust.
Read the entire page →

Key Terms

  • citizen councils
  • clinical excellence
  • address risk
  • novel approaches
  • replace current

  • damages public
  • postmarketing safety
  • validate improved
  • marketed pharmaceuticals
  • drug application

  • move forward
  • regulatory approaches
  • efficacy data
  • risk analysis
  • instituting citizen

  • address novel
  • postmarketing surveillance
  • data concerning
  • specific initiatives
  • fee act

  • evaluating drug
  • drug safety
  • imminent reauthorization
  • critical element
  • pharmaceutical pricing

  • meeting participants
  • communicating pharmaceutical
  • initiatives suggested
  • consider instituting
  • quantitative tools


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.